Skip to main content
    I

    Insmed Inc (INSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $122.88
    +1.72 (+1.42%)

    Market Cap: $26.58B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insmed Inc (INSM) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Insmed (INSM) trades at 17.7x sales and 37.0x book value. Its P/S of 17.7x is above its 5-year median of 16.3x. Its forward P/E is 107.5x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E107.5x
    Price to sales17.7x
    Price to book37.0x
    PEGN/A
    FCF yield-2.3%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 242.6% above 10.8x.

    MultipleCurrent5-year median10-year median
    P/S17.7x16.3xN/A
    P/B37.0xN/A10.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 102 months (10-year).

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/S, its P/S ranged from 10.0x in 2022 to 102.8x in 2018.

    Year endPriceP/SP/B
    2025$174.0458.2x50.3x
    2024$69.0431.2x43.3x
    2023$30.9914.3xN/A
    2022$19.9810.0x30.1x
    2021$27.2416.2x7.9x
    2020$33.2919.8x12.3x
    2019$23.8815.0x8.2x
    2018$13.12102.8x4.9x
    2017$31.18N/A6.6x
    2016$13.23N/A5.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About INSM

    What is INSM's forward P/E ratio?

    Insmed has a forward P/E ratio of 107.5x.

    Is INSM stock overvalued?

    GNG's valuation label for INSM is Fairly valued.

    What is INSM's price to sales ratio?

    Insmed has a price to sales ratio of 17.7x.